ORCID Profile
0000-0001-9339-283X
Current Organisations
Universitas Islam Bandung
,
Universitas Padjadjaran
,
Consiglio Nazionale delle Ricerche
,
Università degli Studi di Padova
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: F1000 Research Ltd
Date: 27-10-2021
DOI: 10.12688/F1000RESEARCH.73606.1
Abstract: Background: Evidence of highly effective repurposed drugs for coronavirus disease 2019 (COVID-19) is insufficient. However, empirical therapy using antiviral, antibiotic and immunomodulatory drugs is massive. Studies evaluating the clinical use of these drugs in Indonesia are sparse. Methods: We performed a retrospective study using medical records of hospitalized COVID-19 patients from July 2020 to March 2021 in Bandung, Indonesia. Data were collected at relevant timelines: age, sex, comorbid condition, peripheral oxygen saturation (SpO 2 ), and hematology at admission antiviral, antibiotic, and immunomodulator treatment during hospitalization length of stay hospitalization (LOS) and death at discharge. Clinical use of the drug regimens included dose, frequency, and duration of therapy. The main outcome of hospitalization care was LOS and death. Results: Out of 249 patients, 43.3% had a comorbid condition, 74.7% had non-severe COVID-19 (SpO 2 ≥ 90%), and almost all received antiviral or antibiotic agents. Remdesivir was the most frequent drug composing various antiviral regimens. Patients receiving a combination of remdesivir and favipiravir had lower SpO 2 compared to those receiving oseltamivir (p=0.01). The short LOS was associated with remdesivir alone (p=0.03), the combination of favipiravir and oseltamivir (p=0.01), and the combination of intravenous levofloxacin and ceftriaxone (p .0001). Immunomodulatory drugs (methylprednisolone, dexamethasone, tocilizumab) were used in 47.1% of patients with low SpO 2 (p=0.001). Its use was associated with prolonged LOS (p=0.0043). The increased risk of death in patients treated with the combination of remdesivir and favipiravir (OR 4.1 %CI 1.4-12.2), and immunomodulatory drugs (OR 6.2 95%CI 1.7-23.3) was confounded by the baseline characteristics of older age, comorbid condition, SpO 2 level, and low lymphocyte number. Conclusions: Some treatment regimens were associated with short LOS, but there were drug regimens which might increase the risk of death. Further study should control the clinical conditions of COVID-19 patients at admission to confirm the outcome of death following drug therapy.
Publisher: F1000 Research Ltd
Date: 28-07-2023
DOI: 10.12688/F1000RESEARCH.73606.2
Abstract: Background: Evidence of highly effective repurposed drugs for coronavirus disease 2019 (COVID-19) is insufficient. However, empirical therapy using antiviral, antibiotic and immunomodulatory drugs is massive. This study aimed to evaluate the clinical use of these drugs and the outcome of hospitalization in COVID-19 patients. Methods: We performed a retrospective study using medical records of hospitalized COVID-19 patients from July 2020 to March 2021 in Bandung, Indonesia. Data were collected at relevant timelines: age, sex, comorbid condition, peripheral oxygen saturation (SpO 2 ), and hematology at admission antiviral, antibiotic, and immunomodulator treatment during hospitalization length of stay hospitalization (LOS) and death at discharge. Clinical use of the drug regimens included dose, frequency, and duration of therapy. The main outcome of hospitalization was LOS and death. Results: Out of 249 patients, 43.3% had a comorbid condition, 74.7% had non-severe COVID-19 (SpO 2 ≥ 90%), and almost all received antiviral or antibiotic agents. Patients receiving a combination of remdesivir and favipiravir had lower SpO 2 compared to those receiving oseltamivir alone (p=0.01). Remdesivir alone and combination of favipiravir and oseltamivir had shorter LOS compared to the other antivirals (p=0.03 and p=0.01 respectively). Immunomodulatory drugs (methylprednisolone, dexamethasone, tocilizumab) were prescribed in patients with lower baseline SpO 2 (p=0.001) and resulted ini longer LOS (p=0.0043) compared to those with no immunomodulators. The increased risk of death in patients treated with the combination of remdesivir and favipiravir (OR 4.1 %CI 1.4-12.2), and immunomodulatory drugs (OR 6.2 95%CI 1.7-23.3) was confounded by the baseline characteristics of older age, comorbid condition, SpO 2 level, and low lymphocyte number. Conclusions: Some treatment regimens were associated with short LOS, but there were drug regimens which might increase the risk of death. Further study should control the clinical conditions of COVID-19 patients at admission to confirm the outcome of death following drug therapy.
Publisher: IOP Publishing
Date: 15-06-2017
Publisher: Springer Science and Business Media LLC
Date: 19-06-2017
DOI: 10.1038/NPHYS4167
Publisher: American Physical Society (APS)
Date: 30-07-2013
Publisher: IOP Publishing
Date: 26-09-2013
No related grants have been discovered for David Terranova.